Partial
Partially Aligned
Patient Risk:
Moderate
Summary
The response includes multiple on-label safety/monitoring statements (e.g., hepatotoxicity, myelosuppression, hypersensitivity, and monitoring frequency) that are supported by the provided label sections. However, several key claims are unsupported or missing necessary label qualifiers (e.g., explicit 'low-dose' definition, severity qualifiers for indications, and several consequence statements like dehydration/electrolyte imbalance), and some specific phrasing (e.g., 'valuable treatment option') is not found in the provided sections.
Category Scores
Accurate Statements
Liver damage is a serious adverse effect of low-dose methotrexate.
Section 5.5: hepatotoxicity described as 'severe and potentially irreversible, including fibrosis, cirrhosis, and fatal liver failure.'
Methotrexate-related liver damage can lead to liver failure.
Section 5.5: includes 'fatal liver failure.'
Methotrexate-related liver damage can result in death.
Section 5.5: 'fatal liver failure.'
Bone marrow suppression is a serious adverse effect of low-dose methotrexate.
Section 5.3: 'suppress[es] hematopoiesis' and can cause severe/life-threatening pancytopenia and cytopenias.
Low-dose methotrexate can suppress bone marrow function, leading to decreased white blood cells, red blood cells, and platelets.
Section 5.3: pancytopenia with 'anemia, leukopenia, neutropenia, and thrombocytopenia.'
Severe allergic reactions are a serious adverse effect of methotrexate.
Section 5.2: hypersensitivity reactions including anaphylaxis; discontinuation guidance in Section 2.6.
Methotrexate can cause severe allergic reactions including anaphylaxis.
Section 5.2: 'including anaphylaxis, can occur with TREXALL.'
Anaphylaxis associated with methotrexate can be life-threatening.
Section 5.2 frames anaphylaxis as a serious hypersensitivity reaction with immediate/permanent discontinuation (and also treated as severe in 2.6).
Patients taking low-dose methotrexate should have regular blood tests to monitor liver function.
Section 5.5: 'Monitor liver tests at baseline, periodically during treatment and as clinically indicated.'
Patients taking low-dose methotrexate should have regular blood tests to monitor kidney function.
Section 5.8: 'Monitor renal function at baseline, periodically during treatment and as clinically indicated.'
Patients taking low-dose methotrexate should have regular blood tests to monitor blood cell counts.
Section 5.3: 'Obtain blood counts at baseline, periodically during treatment...'
Dosage adjustments may be necessary to minimize side effects and optimize treatment with low-dose methotrexate.
Sections 2.6, 5.3, 5.4, 5.5, and 5.8: withhold/dose reduce/discontinue guidance tied to adverse reactions and monitoring.
Patients should be educated on the potential side effects of low-dose methotrexate and how to manage them.
Section 17: counseling to report specific adverse reactions and seek care; repeated monitoring/reporting instructions.
Careful monitoring and dosage adjustments are essential to minimize side effects with low-dose methotrexate.
Sections 5.3, 5.4, 5.5, 5.8 and 2.6 emphasize monitoring and withhold/dose modification actions.
Unsupported Statements
Low-dose methotrexate typically refers to doses of 2.5-10 mg per week.
No dose-range definition for 'low-dose methotrexate (2.5–10 mg/week)' is present in the provided label sections.
Nausea and vomiting with low-dose methotrexate are usually mild and temporary.
The provided label sections do not state that nausea/vomiting are 'usually mild and temporary.'
Diarrhea caused by low-dose methotrexate can lead to dehydration.
No dehydration consequence is described in the provided label sections.
Diarrhea caused by low-dose methotrexate can lead to electrolyte imbalances.
No electrolyte imbalance consequence is described in the provided label sections.
Headaches with low-dose methotrexate can range from mild to severe.
The provided label sections identify headache as an adverse reaction but do not describe a severity range.
Stomach upset with methotrexate can include abdominal pain, cramping, and bloating.
The provided label sections do not list abdominal pain/cramping/bloating as components of 'stomach upset.'
Patients with a history of bone marrow suppression should consult with their healthcare provider before taking low-dose methotrexate, as it may not be suitable for them.
The provided label sections include monitoring and withhold/dose modification for myelosuppression (5.3/2.6) but do not include an explicit consult-before-use statement based on prior bone marrow suppression.
Low-dose methotrexate is described as a valuable treatment option for many patients.
No 'valuable treatment option' wording appears in the provided label sections.
Contradictions
Important Omissions
Boxed warning/contraindication context and explicit contraindication details relevant to pregnancy and hypersensitivity are not assessed because the prompt did not provide the corresponding label sections beyond limited extracts.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several supported safety/monitoring claims were made, but multiple unsupported consequence/severity and dosing-definition claims (e.g., dehydration/electrolyte imbalance; 'usually mild and temporary'; 'low-dose' dose-range definition) could lead to misinterpretation of risk or expectations not grounded in the provided label text.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Multiple claims use severity/consequence and dosing-definition language ('low-dose' range, mild/temporary course, dehydration/electrolyte imbalance, severity range of headache, 'stomach upset' components) that are not supported by the provided label sections.
Suggested Improvement
Remove or rephrase unsupported claims and tie adverse effect descriptions to the label’s specific adverse reaction terms and monitoring/withhold/dose modification language; avoid adding severity or mechanistic consequences not present in the provided label text. For indications, use label qualifiers (e.g., 'severe psoriasis'; 'adults with rheumatoid arthritis') exactly as stated.